Unigestion Holding’s Vertex Pharmaceuticals VRTX Stock Holding History

Unigestion Holding’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,743	Closed	-$1.12M	–	189
2024 Q2	$1.12M	Buy	+2,743	New	+$1.19M	0.06%	102
2024 Q1	–	Sell	-2,743	Closed	-$1.12M	–	159
2023 Q4	$1.12M	Sell	2,743 -72,806	-96%	-$26.9M	0.06%	102
2023 Q3	$26.6M	Buy	75,549 +30	+0%	+$10.5K	1.63%	22
2023 Q2	$26.3M	Sell	75,519 -29,652	-28%	-$9.99M	1.52%	23
2023 Q1	$32.8M	Sell	105,171 -55	-0.1%	-$16.5K	1.78%	18
2022 Q4	$30.4M	Buy	105,226 +8,161	+8%	+$2.49M	1.61%	20
2022 Q3	$28.4M	Buy	97,065 +92,577	+2,063%	+$26.6M	1.65%	19
2022 Q2	$1.26M	Buy	+4,488	New	+$1.2M	0.07%	122
2020 Q4	–	Sell	-1,210	Closed	-$329K	–	250
2020 Q3	$329K	Sell	1,210 -1,095	-48%	-$302K	0.01%	172
2020 Q2	$670K	Buy	+2,305	New	+$625K	0.02%	143

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Unigestion Holding's VRTX Position: Q3 2024 in Review

Unigestion Holding sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 2,743 shares — an estimated $1.12M sold.

Unigestion Holding first reported a position in VRTX in Q2 2020 and held it in 10 quarters. The position peaked at $32.8M in Q1 2023. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

Unigestion Holding reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Unigestion Holding sold 2,743 Vertex Pharmaceuticals shares in Q3 2024, an estimated $1.12M.
Unigestion Holding first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 10 quarters.
Unigestion Holding's Vertex Pharmaceuticals position peaked at $32.8M in Q1 2023.
1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Unigestion Holding's 13F filing for Q3 2024, filed 19 Nov 2024.